ArticleBMC gastroenterology2026
Assessment of the impact of furosemide use on outcomes in patients with intra-abdominal hypertension: a retrospective cohort study from the MIMIC-IV database.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveThis study aims to explore the effect of furosemide on the prognosis of patients with intra-abdominal hypertension (IAH).
methodsA retrospective cohort study was conducted utilizing data extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The analysis encompassed adult patients diagnosed with intra-abdominal hypertension. The exposure factor in this study was defined as the administration of furosemide during the intensive care unit (ICU) stay. The primary outcome measured was all-cause mortality at 28 days, while the secondary outcomes included all-cause mortality at 7 days, 90 days, and 180 days. Both propensity score matching (PSM) and COX multivariate regression analysis were employed to adjust for potential confounding variables.
resultsA total of 859 critically ill patients with IAH were enrolled, with 534 receiving furosemide and 325 not. After PSM, mortality was significantly higher in the non-furosemide group across all time points (7 days: 6.7% vs. 27.3%; 28 days: 25.3% vs. 47.8%; 90 days: 30.0% vs. 50.6%; 180 days: 30.8% vs. 50.6%; all P < 0.001). Multivariate COX regression analysis identified furosemide use as a protective factor for 7-day, 28-day, 90-day, and 180-day all-cause mortality in IAH patients (7-day: HR = 0.19, 95%CI 0.11–0.34, P < 0.001; 28-day: HR = 0.35, 95%CI 0.26–0.48, P < 0.001; 90-day: HR = 0.39, 95%CI 0.29–0.52, P < 0.001; 180-day: HR = 0.40, 95%CI 0.30–0.54, P < 0.001). Subgroup analysis confirmed consistent beneficial effects across different baseline characteristics.
conclusionFurosemide use was associated with reduced all-cause mortality in critically ill patients with IAH. Additional high-caliber prospective investigations are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.